Candidemia Clinical Trial
Candidemia is the fourth leading cause of hospital-acquired infection in USA. In CMUH, it
caused 9% hospital-acquired bloodstream infection in 2008 and 2009. In addition to increased
mortality, candidemia also increased hospital stay and cost. There is a trend of increased
cases of candidemia in recent years in CMUH. Early empirical and target treatment can reduce
mortality and shortened length of hospital stay.
In the past, most prior studies in Taiwan dealt with risk factors for mortality rather than
for candidemia and also focused at in vitro susceptibility to antifungal agents. In this
study, the investigators hope to analyze the candidemic cases from 2003 to 2009, estimated
1000 cases. There were some rare Candida species. Therefore, the investigators hope to do
case study for these diseases to provide the epidemiology of candidemia in CMUH. The result
can help clinician in predicting the disease and its outcome. Besides, it also provides the
epidemiology of candidemia in mid-Taiwan.
n/a
Observational Model: Case-Only, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01982071 -
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
|
Phase 4 | |
| Completed |
NCT02244606 -
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
|
Phase 2 | |
| Completed |
NCT02163889 -
Serial Therapeutic and Antifungal Monitoring Protocol
|
||
| Recruiting |
NCT01438216 -
Anidulafungin Pharmacokinetics in Intensive Care Unit Patients
|
N/A | |
| Completed |
NCT00940017 -
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
|
Phase 4 | |
| Terminated |
NCT01213823 -
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
|
Phase 4 | |
| Completed |
NCT00105144 -
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
|
Phase 3 | |
| Completed |
NCT03667690 -
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
|
Phase 3 | |
| Completed |
NCT03604705 -
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
|
Phase 2 | |
| Completed |
NCT00607763 -
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
| Completed |
NCT00608335 -
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
|
Phase 1 | |
| Recruiting |
NCT04147975 -
Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood
|
||
| Completed |
NCT01734525 -
Negative Beta Glucan in ICU Patients
|
Phase 4 | |
| Withdrawn |
NCT01622595 -
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
|
N/A | |
| Completed |
NCT03363841 -
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
|
Phase 3 | |
| Completed |
NCT03799172 -
Echinocandins Versus Azoles for Candidemia Treatment
|
||
| Completed |
NCT01406093 -
Early- and Late-onset Candidemia
|
N/A | |
| Completed |
NCT00670657 -
CRITIC - Treatment of Candidemia and Invasive Candidiasis
|
Phase 4 | |
| Completed |
NCT00113191 -
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
|
N/A | |
| Recruiting |
NCT04368559 -
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
|
Phase 3 |